Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Trellus Health Plc | LSE:TRLS | London | Ordinary Share | GB00BNNFM402 | ORD GBP0.0006 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.025 | -3.57% | 0.675 | 17,213 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.65 | 0.70 | 0.675 | 0.675 | 0.675 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Offices Of Medical Doctors | USD 19k | USD -6.34M | USD -0.0392 | -0.17 | 1.13M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 11:40:33 | O | 7,692 | 0.65 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 30/9/2024 | 06:00 | UK RNS | Trellus Health PLC Holding(s) in Company |
| 26/9/2024 | 17:12 | ALNC |  EARNINGS: Zephyr Energy interim loss narrows; Eqtec expenses surge |
| 26/9/2024 | 06:00 | UK RNS | Trellus Health PLC Half-year Report |
| 19/9/2024 | 06:00 | UK RNS | Trellus Health PLC Directorate Change |
| 16/9/2024 | 06:00 | UK RNS | Trellus Health PLC Notice of Results |
| 15/7/2024 | 17:07 | UK RNS | Trellus Health PLC Holding(s) in Company |
| 26/6/2024 | 06:00 | UK RNS | Trellus Health PLC Holding(s) in Company |
| 24/6/2024 | 16:15 | UK RNS | Trellus Health PLC Holding(s) in Company |
| 19/6/2024 | 14:53 | UK RNS | Trellus Health PLC Holding(s) in Company |
| 14/6/2024 | 16:19 | UK RNS | Trellus Health PLC Holding(s) in Company |
Trellus Health (TRLS) Share Charts1 Year Trellus Health Chart |
|
1 Month Trellus Health Chart |
Intraday Trellus Health Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 31/10/2024 | 11:02 | Trellus Health - Digital Health Solution for complex chronic conditions | 382 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 11:40:34 | 0.65 | 7,692 | 50.00 | O |
| 11:20:55 | 0.65 | 4,383 | 28.49 | O |
| 11:20:55 | 0.65 | 120 | 0.78 | O |
| 11:20:55 | 0.65 | 4,713 | 30.63 | O |
| 11:20:55 | 0.65 | 80 | 0.52 | O |
| Top Posts |
|---|
Posted at 21/11/2024 08:20 by Trellus Health Daily Update Trellus Health Plc is listed in the Offices Of Medical Doctors sector of the London Stock Exchange with ticker TRLS. The last closing price for Trellus Health was 0.70p.Trellus Health currently has 161,508,333 shares in issue. The market capitalisation of Trellus Health is £1,082,106. Trellus Health has a price to earnings ratio (PE ratio) of -0.17. This morning TRLS shares opened at 0.68p |
Posted at 31/10/2024 11:02 by tomboyb Probably the easiest Job in the world -Sit back / relax /spend and when money runs out point out market conditions - Those TRLS videos are there to see - No shame - |
Posted at 17/10/2024 10:53 by wan Trellus Health® is commercializing the provision of digital chronic condition management solutionsTrellus' cash position is currently circa £4-5m, with a market cap currently at £1.2m. Whilst I don't dispute the dire performance in terms of both share price performance and commercial progress, it appears quite clear that Trellus Health's features and capabilities cost a lot more to develop and market compared to the current market cap (shareholders have certainly paid for it!), and even including the possibility of a significant bid premium, not to mention the current cash position, another player could acquire what appears to be a very cheap option. Even a significant premium to the current share price could still be below the cash position, and with some companies in the sector apparently looking for strategic acquisitions that will add new features and capabilities into their products, Trellus could arguably be on certain radars. Particularly as a key benefit of Trellus' methodology is that its condition-agnostic (it can be utilised in management of many more chronic conditions) and Trellus has revealed that they are in discussions with potential partners across all their commercial models, including two later-stage discussions. The following article provides further food for thought - Digital health deal count declines in Q3, but check sizes stabilize: Rock Health Start ups notched just 110 deals in the third quarter, compared with 133 in the second quarter. But average deal size held steady. Published Oct. 14, 2024 Now, digital health companies are looking to build up their offerings, sometimes through strategic acquisitions, to compete with legacy healthcare firms, according to the latest Rock Health report. The sector has seen relatively few cases of companies acquiring their competitors this year, a type of M&A that drove increased consolidation in 2021 and 2022. But the analysis noted some digital health companies are using M&A to add new features and capabilities into their products, rather than just grow the company overall. That could be especially wise after a period of valuation decline among digital health startups, report authors Adriana Krasniansky, Sari Kaganoff and Tiffany Marie Ramos wrote. “Acquiring a startup with a built-out product and sales, potentially at a depressed price, can be more affordable than building a new product and customer base from scratch,” they said. Full story - As I said previously, I am not holding my breath given the absolutely dire performance to date (I have grudgingly accepted and partly mitigated the near total loss). Please conduct your own research when making investment decisions, as the originator, market commentators, or the threads contributors, could be either wrong or inaccurate. |
Posted at 25/6/2024 11:43 by 12smith Think last of harwood sell now getting mopped up as buy price slipping a tad . |
Posted at 23/4/2024 10:55 by idomeneo Total of 180 downloads (all time):More data about Trellus Health Price Free to download Total downloads 180 Recent downloads 16 Rating No ratings Ranking Not ranked Version 1.96.0 APK size 43.8 MB Number of libraries ? Suitable for Everyone Ads NO ads |
Posted at 19/12/2023 13:46 by hatfullofsky Very strange price action here |
Posted at 01/12/2023 12:24 by hatfullofsky TRLS are now trading 40% below their cash level |
Posted at 03/10/2023 15:10 by hatfullofsky I was waiting for the user numbers too and to hear they have moved the 130 [paying] members $100 / month to a free service as part of a community feedback programme really hurt. There is clearly no demand in the D2C model and that's why they pushed the B2B emphasis on the investor call.If this tool does save money for the payer there is a clear business case. You could see the health care provider making it mandatory for all IBS / IBD sufferers. But the "potential share of savings" being the "significant upside" worries me when they have no users yet 6,200 members at $1,250 is breakeven £7.75m so current cash levels support the 2025 timeline. Their current pilot programmes have a TAM of 325 users and we'll only get results in Q2-24. They alluded to signing a major pilot programme (I guess before year end), that will attract interest and then the results in Q2 but really we are going to be waiting a long time for this to ignite |
Posted at 01/9/2023 12:06 by hatfullofsky Breakeven is on the IMC slide deckAt $100 per patient per month, breakeven at 6200 members (2.5% of TAM)Cash at $19m 2022 v $24m 2021, burn below $700k per month in 2023, cash into 2025 (at current revenue levels and capital investment)In early and late stage discussions with several health plans 2023 expecting revenue take off as 2022 pilot contracts roll into commercial agreements.130 patients currently enrolled (a long way to 6200)TRLS need to announce contracts and enrolment numbers for this to recover |
Posted at 28/2/2023 10:11 by wan Well, do we assume that the delay of around 6 weeks in launching the D2C IBS offering (still ahead of the originally expected launch for IBS in H1 2023) has had a bearing on the delayed TU?Not to mention the progression to late-stage discussions with several pharma co.'s and patient services partners who deliver programs to pharmaceutical companies, is perhaps also taking longer, and I can see that some pharma's have an interest in addressing IBS (and IBD e.g. Takeda), and that a certain patient service partner covers IBS, but not IBD. I am trying to remain somewhat optimistic (but it's wearing thinner by the day) but in any regard, the share price performance since admission to AIM has been utterly uninspiring, and thus the management have a 'lot' to do to change that! |
Posted at 14/12/2021 10:43 by cambridgedon Thanks Wan.Seems that the RENX and TRls share prices are suffering at the same time! In one sense they both represent a lot lower risk than at the IPO/launch price but the recent falls have also got many to question what they are really worth. Thoughts? CD |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
